Why some people develop insulin resistance while others lose insulin-producing capacity

Insulin resistance and declining insulin production are two distinct processes that can occur independently or together in individuals with blood sugar regulation issues. Insulin resistance occurs when muscles, liver, and fat cells become less responsive to insulin, often driven by excess visceral fat releasing inflammatory signals. On the other hand, the pancreas may gradually lose its ability to produce enough insulin, a condition influenced by genetics and long-term cellular stress.

The balance between insulin resistance and declining insulin production can shift over time, explaining why individuals with similar blood sugar levels may have different underlying metabolic problems. The biological factors behind these patterns include genetics, body composition, and lifestyle factors. According to Kanikka Malhotra, Consultant Dietician and Diabetes Educator, insulin resistance develops when certain body tissues become less responsive to insulin, while beta cell decline involves the insulin-producing cells losing function or dying off.

The interplay between genetics, lifestyle, and insulin-producing beta cells plays a crucial role in determining which pathway dominates in an individual. Genetics can influence the number of beta cells a person has and their resilience to stress. As people age, their beta cell efficiency naturally declines. Visceral fat, more prevalent in certain body types, creates a toxic environment that impairs beta cell function.

Diets high in refined carbohydrates and a lack of physical activity can further exacerbate beta cell exhaustion.

Early-stage insulin resistance may prompt the pancreas to produce more insulin, maintaining relatively normal blood sugar levels. However, prolonged insulin resistance and high glucose levels can eventually lead to a decline in beta-cell function. This can alter treatment needs, potentially requiring lifestyle measures, medications that improve insulin sensitivity, or insulin therapy in some cases.

Regular monitoring of glucose levels and C-peptide can help healthcare providers assess changes in insulin production and adjust treatment accordingly.